MOBERG DERMA AB ORD overview

MOB-015 is launched in Sweden under the brand name Terclara- pharmacies report major demand for the new medication PR Newswire STOCKHOLM, Feb. 7, 2024 STOCKHOLM , Feb. 7, 2024 /PRNewswire/ -- Moberg Pharma ABs (OMX: MOB) marker partner in Sweden - Allderma AB, a company which specialises in the sale of over-the-counter (OTC) pharmaceuticals - has now launched sales of MOB-015 under the Terclara ® brand. The interest among pharmacies has been significant for Moberg Pharma's medication against...

MOB-015 is recommended for approval in EU: Moberg Pharma PR Newswire STOCKHOLM, June 28, 2023 STOCKHOLM , June 28, 2023 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) hereby announces that the Decentralized Procedure has ended with a positive outcome and that MOB-015 is recommended for national approval in 13 European countries for the treatment of mild to moderate fungal infections of the nails in adults. The approval in the European Union represents the first marketing authorizations for Moberg...

European marketing authorization application for MOB-015 submitted PR Newswire STOCKHOLM, March 28, 2022 STOCKHOLM , March 28, 2022 /PRNewswire/ -- Moberg Pharma AB (publ) have submitted its marketing authorization application for MOB-015 (nail fungus treatment). The company has submitted the application in Europe through the decentralized procedure, and market approval is expected in 2023. Moberg Pharma have submitted a full application, which offers the possibility of data exclusivity in...

The Medical Products Agency in Sweden will be reference member state for Moberg Pharma's European registration application PR Newswire STOCKHOLM, Dec. 23, 2021 STOCKHOLM , Dec. 23, 2021 /PRNewswire/ -- The Medical Products Agency in Sweden has agreed to be reference member state for Moberg Pharma AB's registration application for MOB-015 (nail fungus treatment). The company will submit the registration application in Europe through the decentralized process, and market approval is expected in...

Moberg Pharma receives approval from the EMA's Paediatric Committee PR Newswire STOCKHOLM, Sept. 22, 2021 STOCKHOLM , Sept. 22, 2021 /PRNewswire/ -- Moberg Pharma AB ( OMX: MOB ) today announces that it has received approval of the pediatric plan for MOB-015 from EMA's paediatric committee (PDCO). This approval enables the company to pursue a full marketing authorization application providing up to ten years of exclusivity in Europe following approval. The company's timeline remains, with...

Moberg Pharmas Year-end report 2020 PR Newswire STOCKHOLM, Feb. 9, 2021 STOCKHOLM , Feb. 9, 2021 /PRNewswire/ -- Financing for both MOB-015 and BUPI PERIOD (JUL 2019- DEC 2020 ) Net revenue SEK 50.5 million (15.6) * EBITDA SEK 19.8 million (-1.7) * Operating profit (EBIT) SEK 16.0 million (-3.0) * Profit after tax SEK 10.2 million (-3.8) * Total profit SEK 8.6 million (499.4) Diluted earnings per share SEK 0.54 (-0.21) * Cash and cash equivalents amounted to SEK 29.3 million (919.1) Comparative...

Moberg Pharma: Announcement of terms for the fully guaranteed rights issue in OncoZenge, timetable for the listing and record date for Lex Asea PR Newswire STOCKHOLM, Jan. 29, 2021 STOCKHOLM , Jan. 29, 2021 /PRNewswire/ -- On November 16, 2020 , OncoZenge AB (publ), Moberg Pharma's subsidiary, announced that the company had secured financing of a total of approximately SEK 70 million ahead of the spin-off and separate listing on Nasdaq First North Growth Market. Today, the Board of Moberg Pharma...

New number of shares and votes in Moberg Pharma AB (publ) PR Newswire STOCKHOLM, Jan. 29, 2021 STOCKHOLM , Jan. 29, 2021 /PRNewswire/ -- During January 2021 , the registered number of shares and votes in Moberg Pharma AB (OMX: MOB) ("Moberg Pharma" or the "Company") has increased due to the completion of the previously announced rights issue, and the final conversion of convertible notes issued pursuant to the financing agreement entered into between the Company and Nice & Green S.A. on March...